As pharma companies continue to scale up digital transformation processes, a survey by GlobalData has highlighted that teaming up with experienced external vendors is driving innovative technology implementation. The leading data and analytics company notes that technologies such as 5G, IoT, sensors, blockchain, cloud and virtual/augmented reality were the top technologies for which pharma companies used external vendors, whereas they were more likely to develop artificial intelligence (AI), big data/analytics or robotics in house comparing to the rest of smart technologies. Leia Mais »
Byondis Appoints Timo van den Berg as Senior Director, Immuno-Oncology R&D
Nijmegen, the Netherlands – 15 July 2021– Byondis B.V. today announced the appointment of Timo K. van den Berg, Ph.D., as senior director, Immuno-Oncology (IO) Research and Development. Van den Berg will assume this role on September 1, operating out of Byondis’ headquarters in Nijmegen.
In his new role, Van den Berg will be instrumental in helping shape Byondis’ IO pipeline, which includes the anti-SIRPα monoclonal antibody BYON4228.
“We are pleased to welcome Timo to the Byondis family. He is a globally recognized IO pioneer, having made important contributions to the field, such as being the first to describe the role of SIRPα and recognizing the potential to use this target to develop a drug for the benefit of cancer patients,” said Byondis Chief Scientific Officer Wim Dokter, Ph.D.
As a longstanding Byondis collaborator, Professor van den Berg played a pivotal role in the discovery of the CD47-SIRPα axis as an innate immune checkpoint. CD47 is known in the IO space as the “don’t eat me” signal that allows tumors to escape recognition and destruction.
“I am very excited about this new chapter in my career,” said Professor van den Berg. “I believe that Byondis and I are well matched. We share the same values, including a strong, goal-oriented work ethic, and a passion for improving patients’ lives by creating precision medicines targeting difficult-to-treat cancers.”
Van den Berg brings to Byondis more than 30 years of experience in the IO field — as a renowned researcher, educator, inventor, lecturer and coauthor of over 175 peer-reviewed publications. His most recent position was head and principal investigator, Immunotherapy Laboratory, Department of Molecular Hematology at Sanquin Research, Amsterdam, the Netherlands. Since 2017, Van den Berg has been professor of Immunotherapy, Vrije Universiteit, which is affiliated with the Department of Molecular Cell Biology and Immunology, Amsterdam University Medical Center. He spent 25 years as research group leader and department head at Amsterdam University Medical Center and Sanquin Research. Sanquin, a non-profit organization responsible for the blood supply in the Netherlands, also develops and produces pharmaceutical products, conducts scientific research and develops and performs diagnostic services.
Van den Berg is a member of many boards, including Amsterdam Infection and Immunity Institute and Cancer Center Amsterdam. His professional memberships include the Dutch Society of Immunology and the European Society for Clinical Investigation. He received his Ph.D. from Amsterdam’s Vrije Universiteit, and his M.Sc. in Biological Sciences (cum laude) from the University of Amsterdam.
About Byondis Leia Mais »
Microbiome is a space with high potential, a fact underlined by the complete absence of microbiome-targeting treatments on the market. This therapeutic area is set to evolve significantly in the coming years as the current pipeline holds numerous potential candidates, with the majority still in early stages of drug development and only four in late-stage trials for gastrointestinal (GI), dermatological and respiratory indications, says GlobalData, a leading data and analytics company.
GlobalData’s report, ‘Thematic Research: Microbiome-Targeted Therapeutics in Immunology’, reveals that 23 microbiome-targeting therapeutics are currently being developed in the US and the *5EU for GI, dermatological, and respiratory conditions. Each of these therapies aims to address these diseases by manipulating the microbiome.
Chris Pilis, Immunology Analyst at GlobalData, comments: “Most microbiome-targeting agents in the pipeline are in early stages of development: roughly half are in Phase I and half are in Phase II. Out of the 23 drugs, 13 are being investigated for GI indications, with the majority targeting ulcerative colitis (UC), whereas six and four are being developed for dermatological and respiratory conditions, respectively. Notably, many of the microbiome-targeting drugs for dermatological and respiratory indications are oral formulations, likely targeting these diseases via the gut-skin and gut-lung axes, respectively.”
The space is currently dominated by small- and mid-size biotech, however, Big Pharma players such as Takeda and Johnson & Johnson have shown increasing interest in this space lately with the development of the Phase II agent Sibofimloc (NCT03943446), and Phase I agent JNJ-72537634 (NCT03931447), respectively. Four therapies are in late-stage Phase II trials: 4D Pharma’s Blautix for irritable bowel syndrome (IBS), AOBiome’s B-244 for acne vulgaris and atopic dermatitis (AD), Evelo Biosciences’ EDP-1815 for psoriasis, and Seres Therapeutics’ SER-287 for UC. Of these agents, key opinion leaders interviewed by GlobalData were particularly enthusiastic about the prospects of 4D Pharma’s Blautix and AOBiome’s B-244, as both agents have already demonstrated promising data in Phase Ib or in early Phase II trials.
Pilis notes: “Decreased biodiversity and imbalance of bacterial levels in the gut microflora are involved in IBS manifestation, which is what Blautix is aiming to address. It is an oral formulation that releases single strains of commensal Blautia hydrogenotrophica that consume H2 gases causing bloating during the disease. The drug also induces acetate production, which promotes gut health, and increases microbiome diversity, ultimately trying to tackle both cause and effect of the disorder. Blautix is currently being evaluated in a Phase IIb trial (NCT03721107), but has exhibited encouraging efficacy and safety results in a previous Phase Ib trial.
“What is most promising about this candidate is that it is under investigation for both sub-groups of IBS-C and IBS-D patients, which until now have had very different therapeutic regimens. If successful, Blautix would be the first marketed product capable of treating both conditions. Consequently, this product could also be effective in treating IBS-M patients (one third of IBS cases) who to date have no treatments approved by the FDA or EMA. Ultimately, Blautix could have a strong impact on the market by being the first microbiome-targeting therapy for IBS and the first treatment approved for both IBS-C and IBS-D, which may potentially grant Blautix the exclusive market share of IBS-M patients.”
B-244 is a topical product under development by AOBiome for the treatment of acne and AD. GlobalData expects this product may gain popularity if marketed as a more ‘natural’ alternative to topical retinoids in acne and/or corticosteroids in AD. Thus far, B-244 has displayed good efficacy and tolerability for both acne and AD. It is currently in a Phase IIb trial (NCT04490109) for mild-to-moderate AD and has already been evaluated in a Phase IIb trial for mild-to-moderate acne (NCT02832063).
Pilis adds: “Although AOBiome read out positive data for NCT02832063 in 2017, the company has seemingly stalled development of B-244 in acne, possibly prioritizing launch of the drug in AD. If successful in clinical trials, B-244 will be the first skin microbiome-targeting drug to enter the market. GlobalData believes its unique mechanism of action and potential to manage two distinct conditions may lead to strong uptake by patients.
“Products such as Blautix and B-244 in particular are microbiome-targeting candidates setting high expectations, by either meeting the unmet needs of difficult-to-treat patients or by addressing multiple indications.”
*5EU: France, Germany, Italy, Spain, UK
A dynamic and contemporary new website from Clarity Pharma, part of Clarity Global Group, demonstrates the breadth of services it offers to mid-market pharmaceutical and healthcare companies around the world seeking new opportunities in the UK healthcare market.
The 2020 Olympic Games in Tokyo will take place from July 23 to August 8, 2021, with a one-year delay due to the COVID-19 pandemic; however, it is unclear, yet, if the country and the world is ready for a global spectacle of that size, says GlobalData, a leading data and analytics company. Leia Mais »
Anti-amyloid therapies show potential for Alzheimer’s after breakthrough designation, says GlobalData
Eisai and Biogen’s lecanemab (BAN2401) and Eli Lilly’s donanemab have recently received breakthrough therapy designation (BTD) by the US Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease (AD). The potential approval of lecanemab and donanemab will increase the number of disease-modifying treatments (DMTs) available that target and affect the underlying disease progression of AD, says GlobalData, a leading data and analytics company. Leia Mais »
First results of the European AURORA study: towards a better understanding of the molecular changes driving metastatic breast cancer
AURORA is an international academic research programme based on molecular screening and is dedicated to improving our understanding of metastatic breast cancer. Leia Mais »
The Tokyo Olympics will likely be an epicenter of transmission for COVID-19 and could increase variant of concern (VOC) spread, bringing new cases to Japan and new cases back to home countries, says GlobalData, a leading data and analytics company. Leia Mais »
Euretos provides free access to its AI Platform for academic researchers to further support early disease and drug research
- Free access for academic users to Euretos AI Platform
- Access to the world’s most extensive machine-read knowledgebase focused on molecular disease and drug research
- The Euretos AI Platform is already proven in some of the largest pharma and biotech companies in the world
The ease by which mRNA-based drugs are taken up by cells in tissues is crucial to their therapeutic effectiveness. Now, a new detection method developed by researchers at Chalmers University of Technology, Sweden, and AstraZeneca could lead to faster and better development of the small droplets known as lipid nanoparticles, which are the main method used to package mRNA for delivery to the cells. Leia Mais »